CA3005909A1 - Compositions and methods for treating ischemic stroke - Google Patents

Compositions and methods for treating ischemic stroke Download PDF

Info

Publication number
CA3005909A1
CA3005909A1 CA3005909A CA3005909A CA3005909A1 CA 3005909 A1 CA3005909 A1 CA 3005909A1 CA 3005909 A CA3005909 A CA 3005909A CA 3005909 A CA3005909 A CA 3005909A CA 3005909 A1 CA3005909 A1 CA 3005909A1
Authority
CA
Canada
Prior art keywords
cromolyn
compound
stroke
brain
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3005909A
Other languages
English (en)
French (fr)
Inventor
David Elmaleh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
Aztherapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aztherapies Inc filed Critical Aztherapies Inc
Publication of CA3005909A1 publication Critical patent/CA3005909A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3005909A 2015-11-23 2016-11-23 Compositions and methods for treating ischemic stroke Pending CA3005909A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562258882P 2015-11-23 2015-11-23
US62/258,882 2015-11-23
PCT/US2016/063462 WO2017091644A1 (en) 2015-11-23 2016-11-23 Compositions and methods for treating ischemic stroke

Publications (1)

Publication Number Publication Date
CA3005909A1 true CA3005909A1 (en) 2017-06-01

Family

ID=58764360

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3005909A Pending CA3005909A1 (en) 2015-11-23 2016-11-23 Compositions and methods for treating ischemic stroke

Country Status (9)

Country Link
US (2) US20180344682A1 (enExample)
EP (1) EP3380095B1 (enExample)
JP (1) JP2018538273A (enExample)
KR (1) KR20180081812A (enExample)
CN (1) CN108472275A (enExample)
AU (1) AU2016359674A1 (enExample)
CA (1) CA3005909A1 (enExample)
MX (1) MX390748B (enExample)
WO (1) WO2017091644A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP2911664B1 (en) 2012-10-25 2019-05-08 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
AU2014340182B2 (en) 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
KR20190044647A (ko) 2016-08-31 2019-04-30 더 제너럴 하스피탈 코포레이션 신경변성 질환과 관련된 신경-염증에서 대식세포/미세아교세포
EP3654946A4 (en) 2017-07-20 2021-04-21 AZTherapies, Inc. CROMOLYNE SODIUM AND IBUPROFEN POWDER FORMULATIONS
AU2017442079A1 (en) * 2017-12-04 2020-06-25 The General Hospital Corporation Cromolyn compositions and methods thereof
CA3096545A1 (en) * 2018-04-09 2019-10-17 The General Hospital Corporation Combination therapies for the treatment of amyotropic lateral sclerosis and related disorders
CA3105392A1 (en) 2018-07-02 2020-01-09 The General Hospital Corporation Powdered formulations of cromolyn sodium and .alpha.-lactose
CA3122989A1 (en) 2018-12-10 2020-06-18 The General Hospital Corporation Cromolyn esters and uses thereof
JP2023520580A (ja) 2020-04-06 2023-05-17 ザ ジェネラル ホスピタル コーポレイション コロナウイルス誘発炎症状態の処置方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1601380A1 (en) * 2003-02-13 2005-12-07 Licentia OY Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia
EP1789057B1 (en) * 2004-08-30 2010-02-24 Seo Hong Yoo Neuroprotective effect of solubilized udca in focal ischemic model
CA2751125C (en) * 2009-01-29 2017-06-20 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US9925282B2 (en) * 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
MX2011009362A (es) * 2009-03-05 2011-09-26 Abbott Lab Proteinas de union a il-17.
JP2012520311A (ja) * 2009-03-11 2012-09-06 プレキシコン インコーポレーテッド Ｒａｆキナーゼの阻害のためのピロロ［２，３−ｂ］ピリジン誘導体
EP2911664B1 (en) * 2012-10-25 2019-05-08 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
MX381503B (es) * 2013-05-23 2025-03-12 Aztherapies Inc Métodos para la liberación de cromolina.
AU2014340182B2 (en) * 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
WO2015120389A1 (en) * 2014-02-10 2015-08-13 Patara Pharma, LLC Mast cell stabilizers treatment for systemic disorders
KR20190044647A (ko) * 2016-08-31 2019-04-30 더 제너럴 하스피탈 코포레이션 신경변성 질환과 관련된 신경-염증에서 대식세포/미세아교세포

Also Published As

Publication number Publication date
AU2016359674A1 (en) 2018-06-14
KR20180081812A (ko) 2018-07-17
EP3380095A4 (en) 2019-10-23
JP2018538273A (ja) 2018-12-27
WO2017091644A1 (en) 2017-06-01
MX2018006390A (es) 2019-02-14
US20220125753A1 (en) 2022-04-28
CN108472275A (zh) 2018-08-31
EP3380095A1 (en) 2018-10-03
US20180344682A1 (en) 2018-12-06
EP3380095B1 (en) 2022-01-05
MX390748B (es) 2025-03-21

Similar Documents

Publication Publication Date Title
US20220125753A1 (en) Compositions and methods for treating ischemic stroke
US20240058480A1 (en) Cromolyn derivatives and related methods of imaging and treatment
US10245331B2 (en) Cromolyn derivatives and related methods of imaging and treatment
EP2560624B1 (en) Therapeutic formulation for reduced drug side effects
JP2024161363A (ja) 安定なカンナビノイド製剤
US10058530B2 (en) Combination therapies for the treatment of Alzheimer's disease and related disorders
HK1226940A1 (zh) 用拉喹莫德与醋酸格拉替雷的组合治疗多发性硬化症
KR20140054129A (ko) 라퀴니모드와 인터페론-베타의 병용에 의한 다발성 경화증의 치료
TW201505634A (zh) 藥物戒斷之無毒治療方法
EP4114403B1 (en) Treating neuropathic pain associated with chemotherapy-induced peripheral neuropathy
US20120065181A1 (en) Method of providing neuroprotection using substituted porphyrins
JP2024521736A (ja) 筋萎縮性側索硬化症の治療に使用するためのケルセチン含有組成物
JP6258264B2 (ja) ヒトの血小板レベルを増加させるための組成物および方法
KR20090024248A (ko) Ｃｘｃｒ2의 선택적 길항제 또는 ｃｘｃｒ1과 ｃｘｃｒ2 둘다의 선택적 길항제의 약제학적 제형 및 조성물, 및 염증성 질환을 치료하기 위한 이의 사용방법
KR20100040281A (ko) 실로스타졸과 은행잎 추출물을 함유한 약제 조성물
US20240285548A1 (en) Agent for prevention and/or treatment of cognitive impairment
EP4670737A1 (en) PHARMACEUTICAL PRODUCT FOR THE TREATMENT OR PREVENTION OF PERIPHERAL NEUROPATHY
JP2016533323A (ja) 多発性硬化症の治療のためのラキニモド併用療法
WO2023180956A1 (en) Methods of using avermectin compositions for the treatment of spasticity and dosing regimens
KR20100112293A (ko) 데스로라타딘을 포함하는 안과용 조성물
Maile et al. Early morning recurrent chest pain
HK1170673B (en) Compositions and methods for increasing blood platelet levels in humans

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211119

EEER Examination request

Effective date: 20211119

EEER Examination request

Effective date: 20211119

EEER Examination request

Effective date: 20211119

EEER Examination request

Effective date: 20211119

EEER Examination request

Effective date: 20211119

EEER Examination request

Effective date: 20211119